{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H1",
"title": "Impaired TFEB Nuclear Import as Primary Driver, Not Compensatory Failure",
"composite_score": 0.52,
"dimension_scores": {
"mechanistic_plausibility": 0.82,
"evidence_strength": 0.48,
"novelty": 0.55,
"feasibility": 0.62,
"therapeutic_potential": 0.58,
"druggability": 0.38,
"safety_profile": 0.35,
"competitive_landscape": 0.45,
"data_availability": 0.58,
"reproducibility": 0.52
},
"evidence_for": [
{"claim": "mTORC1 directly phosphorylates TFEB at S211 to control nucleocytoplasmic shuttling", "pmid": "20679224"},
{"claim": "mTORC1 hyperactivation in Alzheimer's disease brains correlates with reduced nuclear TFEB", "pmid": "29727682"},
{"claim": "Pharmacological mTORC1 inhibition restores TFEB nuclear localization and improves clearance in Parkinson's models", "pmid": "25437564"},
{"claim": "TFEB overexpression is sufficient to reduce α-synuclein and tau aggregation in cell models", "pmid": "29515023"},
{"claim": "Direct molecular mechanism (S211 phosphorylation creating 14-3-3 binding site) provides clear testable framework", "source": "Theorist"},
{"claim": "Nuclear TFEB reduction demonstrable before protein aggregates in multiple models", "source": "Theorist assertion"}
],
"evidence_against": [
{"claim": "Temporal causality is correlative, not demonstrated; end-stage tissue studies cannot establish upstream causation", "pmid": "29727682"},
{"claim": "mTORC1 hyperactivation is not specific mechanism - mTORC1 regulates hundreds of substrates beyond TFEB", "pmid": "25437564"},
{"claim": "Temsirolimus Phase II trial in Alzheimer's showed no cognitive benefit", "pmid": "NCT02049343"},
{"claim": "Everolimus Alzheimer's trial terminated with no signal", "pmid": "NCT02336633"},
{"claim": "Conditional neuronal TFEB knockout does not cause rapid/spontaneous neurodegeneration", "source": "Skeptic"},
{"claim": "BBB penetration: Rapamycin has CSF:plasma ratio ~0.05", "source": "Expert"},
{"claim": "Chronic mTORC1 inhibition causes immunosuppression, contraindicated in elderly patients", "source": "Expert"},
{"claim": "S211 is not the only regulatory site - S142 and other sites also regulate TFEB localization", "pmid": "20679224"}
],
"knowledge_edges": [
{"from": "mTORC1", "to": "TFEB", "relation": "phosphorylates_at_S211", "direction": "inhibits_nuclear_import"},
{"from": "14-3-3", "to": "TFEB", "relation": "binds_phosphorylated_S211", "direction": "cytoplasmic_sequestration"},
{"from": "TFEB", "to": "CLEAR_network", "relation": "transcriptionally_regulates", "direction": "upregulates_autophagy"},
{"from": "TFEB", "to": "α-synuclein/tau", "relation": "clearance_target", "direction": "reduces_aggregation"},
{"from": "mTORC1", "to": "S6K/4E-BP1", "relation": "phosphorylates", "direction": "parallel_pathways"},
{"from": "mTORC1_inhibitors", "to": "synaptic_plasticity", "relation": "adverse_effect", "direction": "impairs_memory"}
],
"expert_notes": "Despite clinical failures, the mechanistic foundation remains compelling. Translation failure may reflect timing (late-stage intervention), BBB penetration, or pathway specificity rather than mechanism invalidity."
},
{
"rank": 2,
"hypothesis_id": "H2",
"title": "Biphasic TFEB Response—Compensatory Then Destructive",
"composite_score": 0.48,
"dimension_scores": {
"mechanistic_plausibility": 0.68,
"evidence_strength": 0.52,
"novelty": 0.62,
"feasibility": 0.55,
"therapeutic_potential": 0.72,
"druggability": 0.32,
"safety_profile": 0.42,
"competitive_landscape": 0.40,
"data_availability": 0.45,
"reproducibility": 0.50
},
"evidence_for": [
{"claim": "TFEB expression increases in early Alzheimer's and Parkinson's disease brains", "pmid": "30545709"},
{"claim": "Acute TFEB activation is neuroprotective in multiple models", "pmid": "29727682"},
{"claim": "Chronic activation shows diminishing returns over time", "pmid": "29727682"},
{"claim": "Negative feedback: mTORC1 reactivation and 14-3-3 overexpression follow prolonged TFEB activation", "pmid": "25437564"},
{"claim": "TFEB target genes become progressively silenced in aged neurons despite continued TFEB protein expression", "source": "Aging Methylome Atlas"},
{"claim": "Explains therapeutic window prediction - beneficial early, limited late-stage benefit", "source": "Theorist"}
],
"evidence_against": [
{"claim": "Epigenetic silencing mechanisms (HDAC3, EZH2) predicted but not validated in neurodegeneration models", "source": "Theorist"},
{"claim": "No biomarkers currently exist to identify which phase a patient is in", "source": "Expert"},
{"claim": "Drugging the therapeutic window requires precise